• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

MSF Secures Deals For Key Hepatitis C Medicines, Price A Fraction Of Branded Drug

31/10/2017 by Intellectual Property Watch 1 Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Médecins Sans Frontières (MSF, Doctors Without Borders) announced today that it has secured deals for two key generic hepatitis C medicines, dropping prices dramatically.

In a statement, MSF said it secured generic medicines for sofosbuvir and daclatasvir for as low as US$1.40 per day, or US$120 per 12-week treatment course.

The two medicines were launched in 2013 by Gilead (sofosbuvir) and in 2015 by Bristol-Myers Squibb (BMS) (dacatasvir) for respectively US$1,000, and US$750 per pill, leading to a combination treatment course of US$147,000 per person for a 12-week treatment course, the statement said.

According to the statement, “In 2015, MSF started procuring sofosbuvir and daclatasvir from Gilead and BMS through their ‘access programs’ at a price of $1,400 to $1,800 per 12-week treatment. Today, MSF pays a fraction of that, at $120, sourced from quality-assured generic manufacturers.”

Those two breakthrough medicines show cure rates of up to 95 percent, MSF said, yet access has remained limited because of unaffordable prices, ” leading many countries to reserve treatment only for people with the most advanced stages of the disease.”

“By the end of 2016, three years after sofosbuvir was launched, only an estimated 2.1 million people globally had been treated with the medicines, leaving 69 million people still without access,” MSF said, adding that these high prices have put a major strain on health systems in wealthy countries, where in some cases treatment is being rationed, such as Australia, Canada, Italy, and the United States. This situation is a ” stark reminder of the early days of HIV treatment,” they said.

MSF made the announcement on the eve of the World Hepatitis Summit being held from 1-3 November in Sao Paolo, Brazil.

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"MSF Secures Deals For Key Hepatitis C Medicines, Price A Fraction Of Branded Drug" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, English, Finance, Health & IP, Health Policy Watch, Human Rights, Patents/Designs/Trade Secrets, WHO

Comments

  1. Harley Cox says

    01/11/2017 at 8:02 am

    I would like to question the statement “where in some cases treatment is being rationed, such as Australia,…”
    This contrasts with information from Australian sources.

    A number of hepatitis C treatments have been listed on the PBS since March 2016. The government has committed to investing A$1 billion over five years to treat the 230,000 Australians living with the disease.

    Australia is a leading country in the global response to hep C. Since March 2016, around 40,000 people with hep C have had treatment. An estimated 95% of them have been cured.
    https://theconversation.com/australia-leads-the-world-in-hepatitis-c-treatment-whats-behind-its-success-81760

    Who can access the new cures?

    Anyone in Australia who is living with chronic hepatitis C and who is eligible for Medicare can access the new medicines to cure their hep C. This is regardless of whether or not you are currently injecting drugs or you are accessing treatment for drug dependency, such as opioid substitution therapy (OST)
    http://www.hepatitisaustralia.com/cure-hep-c/

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Top Global Health stories

New WHO Director Tedros’s Opening Vision: People First

Enter The African Medicines Agency, Continent’s First Super-Regulator?

More health stories...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2022 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.